Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: A team of 20 doctors, including surgeons, neurosurgeons, anesthesiologists and nurses, will be deployed to the region of Marche in central Italy for two weeks, Italian ambassador to Ukraine, Davide La Cecilia told Reuters. “The national health service in our country is very stressed. So we badly need medical personnel and are very happy that Ukraine is sending this humanitarian aid,” said La Cecilia at Kiev’s airport, before the medical mission’s departure. Ukrainian Interior Minister Arsen Avakov, who accompanied the ambassador, said Kiev would send more medical aid and disinfectant to Italy in the coming days. “It is an honour for us to help Italy during such tough times. We know that many Ukrainians live and work in Italy. By helping Italy, we are helping our citizens,” said Avakov. Ukraine’s health ministry has reported 1,096 cases, including 28 deaths since March 3, when the first case was recorded. But as thousands of Ukrainians have recently returned home from abroad, the ministry expects a much bigger outbreak ahead. The daily tally of new cases increased to 154 on Saturday from 138 on Friday, up from 62 last Monday. The head of the Ukrainian medical mission, neurosurgeon Andriy Miroshnichenko, said that all the team members volunteered to work in Italy. “After they come back home, they will be able to treat patients and work having practical experience and knowledge about the disease,” said Miroshnichenko. Asked whether the Ukrainian doctors were not afraid to catch the virus themselves Glib Bidyukov, a nurse, said it was “a consciously made choice”. “When you choose healthcare, you understand that you put yourself in some danger… Each of us made a choice a long time ago,” Bidyukov said.
[A]: Ukrainian doctors fly to Italy to help combat coronavirus.


[Q]: Luke Miels, who joined GSK in September 2017 after a contract dispute with his former employer AstraZeneca, said picking the most promising projects and developing them quickly now takes precedence over spreading the risk of failure. “In the past, 10 programs were chosen, a budget for eight was allocated. Usually what happened was that time was the trade off that was made,” he said in an interview. “Now what we do is we pick five or six programs, and concentrate investment there.”   GSK, like rivals, was in the habit of testing new drugs first on patients who had run out of other treatment options. If successful, it would try patients at an earlier stage of their disease, replacing older, established treatments. In today’s market, where rivals in the United States and China catch up fast if a new class of drug shows promise, GSK has to run costly drug tests on humans in several settings at the same time, even if it means dropping other drug candidates. “Rather than do things sequentially, you do them in parallel, or as close to parallel as possible,” Miels said. GSK, which is battling to return to profit growth, has taken this approach for instance with an experimental drug that for now goes by the code name of GSK’916 against multiple myeloma, a common and incurable type of blood cancer. Likewise, GSK doubled down on its quest to bring a drug known as GSK’165 to market as a rheumatoid arthritis treatment, even after initial results in a mid-stage drug trial did not show a clear enough reading. “This drug has very interesting effects on pain. That could potentially reduce the use of opioids and pain meds,” Miels said. More trials will be run to make the pain argument more clearly, he added. GSK expects a decline of 5%-9% in adjusted earnings per share this year, excluding exchange rate moves, as it suffers from generic competition to its inhalable lung drug Advair and pressure from rival Gilead in HIV treatments. Miels said a tougher stance on drug prices by U.S. lawmakers and medical insurers was one of the reasons for the need for speed in bringing drugs to market - to try to remain ahead of competitors for as long as possible. At the same time, rapid growth in the Chinese market was spurring a more sophisticated healthcare system there, with local biotech groups quick to catch up with Western pioneers in drug development, producing similar drugs for their home market.
[A]: GSK pharma head flags need for speed in high-pressure drug market.


[Q]: The U.S. Food and Drug Administration’s partial hold on the so-called STRONG trial impacts patients aged up to five with spinal muscular atrophy (SMA) who were to receive a higher dose of the gene therapy via a spinal infusion. The hold was issued after Novartis told health authorities about the animal study’s findings that showed dorsal root ganglia (DRG) mononuclear cell inflammation, a neurological condition sometimes accompanied by nerve damage or loss. Novartis shares fell 1% at 0715 GMT, while other European drugmakers rose. Analysts said more information was needed to assess whether these findings could have an impact on Zolgensma’s long-term prospects. “We need to better understand, what the issues are and whether there really is a read-through to the human trial,” Vontobel analyst Stefan Schneider said. Novartis said it was working with regulators, in hopes of having the hold released. Zolgensma, whose $2.1 million list price makes it the world’s most-expensive treatment, is already approved for children aged up to two with the deadly muscle wasting disease and is given by infusion into the young patients’ veins. The medicine had $160 million in sales in its first full quarter on the market. The STRONG study is meant to underpin its expanded approval for older children, where Novartis would also compete with Biogen’s Spinraza that is already on the market, and Roche’s investigational risdiplam that is due to seek approval this year. Roche shares were up 0.7%. “The clinical significance of the DRG inflammation observed in this pre-clinical animal study is not known and was not seen in prior animal studies,” Novartis said in a statement. “We are working with health authorities to confirm further guidance to clinical investigators.”  The partial FDA hold halts enrollment of patients getting a higher dose of Zolgensma, also known as AVXS-101, via an spinal infusion, also called intrathecal administration. Low- and mid-dose portions of the STRONG trial have already been completed, as has presentation of interim results. “Of note, we have completed a thorough review of human safety data from all available sources to date and no adverse effects related to sensory changes have been seen,” Novartis said.
[A]:
Novartis' Zolgensma study halted by FDA amid safety questions.